Novel targeted agents used in therapy of lymphoid malignancies are recognized to have complex immune-mediated effects. Sumoylation, a posttranslational modification of target proteins by small ubiquitin-like modifiers (SUMO), regulates a variety of cellular processes indispensable in immune cell activation. Despite this, the role of sumoylation in T-cell biology in context of cancer is not known. TAK-981 (subasumstat) is a small-molecule inhibitor of the SUMO-activating enzyme (SAE) that forms a covalent adduct with an activated SUMO protein. Using T cells derived from patients with chronic lymphocytic leukemia (CLL), we demonstrate that targeting SAE activates type I IFN response. This is accompanied by largely intact T-cell activation in response to T-cell receptor engagement, with increased expression of CD69 and CD38. Furthermore, TAK-981 decreases regulatory T cell (Treg) differentiation and enhances secretion of IFNγ by CD4+ and CD8+ T cells. These findings were recapitulated in mouse models, suggesting an evolutionarily conserved mechanism of T-cell activation regulated by SUMO modification. Relevant to the consideration of TAK-981 as an effective agent for immunotherapy in hematologic malignancies, we demonstrate that the downstream impact of TAK-981 administration is enhancement of the cytotoxic function of CD8+ T cells, thus uncovering immune implications of targeting sumoylation in lymphoid neoplasia.
Novel targeted agents used in therapy of lymphoid malignancies are recognized to have complex immune-mediated effects. Sumoylation, a posttranslational modification of target proteins by small ubiquitin-like modifiers (SUMO), regulates a variety of cellular processes indispensable in immune cell activation. Despite this, the role of sumoylation in T-cell biology in context of cancer is not known. TAK-981 (subasumstat) is a small-molecule inhibitor of the SUMO-activating enzyme (SAE) that forms a covalent adduct with an activated SUMO protein. Using T cells derived from patients with chronic lymphocytic leukemia (CLL), we demonstrate that targeting SAE activates type I IFN response. This is accompanied by largely intact T-cell activation in response to T-cell receptor engagement, with increased expression of CD69 and CD38. Furthermore, TAK-981 decreases regulatory T cell (Treg) differentiation and enhances secretion of IFNγ by CD4+ and CD8+ T cells. These findings were recapitulated in mouse models, suggesting an evolutionarily conserved mechanism of T-cell activation regulated by SUMO modification. Relevant to the consideration of TAK-981 as an effective agent for immunotherapy in hematologic malignancies, we demonstrate that the downstream impact of TAK-981 administration is enhancement of the cytotoxic function of CD8+ T cells, thus uncovering immune implications of targeting sumoylation in lymphoid neoplasia.
AZD4573 induces apoptosis and thwarts survival of MCL cells. A, MCL cell lines were treated with the indicated doses of AZD4573 for 72 hours. Cell proliferation was assessed using a colorimetric tetrazolium-based assay. The mean ± SEM is shown. IC50 value was calculated using GraphPad Prism software set to variable slope. B, Cells were treated with indicated doses of AZD4573 for 8 hours. Apoptosis was determined using Annexin V–FITC staining. Data are the mean ± SEM. *, P < 0.05 and **, P < 0.01 vs. untreated control. C, Primary MCL cells (n = 5 individual samples tested in technical triplicates) were cocultured with stromal cells for 24 hours and then treated with indicated doses of AZD4573 for 24 hours. Apoptosis of the CD19+ B-cell population was quantified using Annexin V–FITC staining. *, P < 0.05 and **, P < 0.01 vs. untreated control. D, Parental and IR MCL cell lines were treated with 10 nmol/L of AZD4573 or vehicle control for the indicated time points. Cell lysates were subjected to immunoblotting. E, Mice were inoculated with MCL. Two distinct MCL PDX models were used. Once circulating CD5+/CD19+ MCL cells were detected in the peripheral blood, mice began treatment as indicated in the methods (n = 3–11 per group). Kaplan–Meier survival curves are shown, with significance determined by the log-rank test. *, P < 0.05; **, P < 0.01.